AbbVie’s $10.1 bn Immunogen deal fortifies oncology portfolio, signals big pharma’s ADC…
Earlier this year, Pfizer acquired ADC giant Seagen for $43 billion in one of the largest M&A deals in industry history
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
non-small cell lung cancer
Alembic Pharma gets USFDA nod for Docetaxel Injection USP
Docetaxcel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric…
AstraZeneca’s Durvalumab gets CDSCO nod to treat locally advanced or metastatic biliary tract cancer
The approval for AstraZeneca molecule is based on the findings of TOPAZ-1, a Phase-3 global clinical trial with patients recruited…
Alembic Pharmaceuticals gets USFDA final approval for Erlotinib Tablets
Erlotinib Tablets are indicated for the treatment of patients with metastatic non-small cell lung cancer and locally advanced,…
AstraZeneca Pharma India gets DCGI approval for Osimertinib tablets
It is now approved as monotherapy for adjuvant treatment after complete tumour resection in patients with NSCLC
Bristol Myers Squibb get EC approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with…
Opdivo plus Yervoy-based combinations now indicated in the EU for three different advanced cancer types: non-small cell lung…
Roche’s Genentech gets US FDA approval for Gavreto (pralsetinib)
The drug is used to treat metastatic RET fusion-positive non-small cell lung cancer
Rozlytrek from Roche gets EC approval to treat solid tumours and NSCLC
The approval is based on results from the integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I…
Merck’s Keytruda shows mixed results in phase 3 trial for small cell lung cancer
While the blockbuster drug showed improvement in overall survival for patients treated with Keytruda in combination with…